| Code | CSB-RA006147MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Pamrevlumab, targeting CCN2 (connective tissue growth factor, CTGF). CCN2 is a matricellular protein that plays a critical role in fibrosis, extracellular matrix remodeling, and tissue repair processes. It mediates cellular adhesion, migration, proliferation, and differentiation through interactions with integrin receptors and other signaling molecules. Aberrant CCN2 expression is implicated in various fibrotic diseases including idiopathic pulmonary fibrosis, pancreatic cancer, liver cirrhosis, and systemic sclerosis, where it promotes excessive collagen deposition and pathological tissue remodeling.
Pamrevlumab is a fully humanized monoclonal antibody that has been investigated in clinical trials for idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy due to its ability to neutralize CCN2 activity. This biosimilar antibody provides researchers with a valuable tool for investigating CCN2-mediated pathways in fibrotic disease models, cancer progression studies, and wound healing research. It enables exploration of therapeutic strategies targeting fibrosis and tissue remodeling across multiple disease contexts.
There are currently no reviews for this product.